SCHEMBL7239028

SCHEMBL7239028

COC(=O)CN(C(=O)OC(C)(C)C)c1ccc(F)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 3/20 0.41
RAB9A P51151 1/20 0.37
MAPT P10636 1/20 0.37
CPB2 Q96IY4 1/20 0.36
GPBAR1 Q8TDU6 3/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
MT-CO2 P00403 1/20 0.35
RIPK1 Q13546 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LTB4R2 Q9NPC1 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
STAT5B P51692 1/20 0.34
CHRNA1 P02708 1/20 0.33
CHRNG P07510 1/20 0.33
CHRNB1 P11230 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715518 0.88 PTGIR (0.37) MLYCDMT-CO2RIPK1LTB4R2HDAC1
SCHEMBL3772650 0.83 MT-CO2 (0.36) MAPTCPB2MT-CO2RIPK1LTB4R2
SCHEMBL3160941 0.81 MT-CO2 (0.38) RAB9AMAPTCPB2MT-CO2RIPK1
SCHEMBL483943 0.81 MLYCD (0.48) MLYCDRAB9AMAPTALDH1A1
SCHEMBL7235054 0.80 RXRA (0.35) ALDH1A1LTB4R2HDAC1HDAC8HDAC6
SCHEMBL1826174 0.80 MLYCD (0.44) MLYCDRAB9AMAPTMT-CO2ALDH1A1
SCHEMBL27451463 0.80 MLYCD (0.44) MLYCDRAB9AALDH1A1STAT5BF2
SCHEMBL3160825 0.80 TSHR (0.37) RAB9AMAPTCPB2MT-CO2RIPK1
SCHEMBL4002016 0.79 MLYCD (0.43) MLYCDRAB9AMAPTALDH1A1POLB
SCHEMBL3503827 0.79 MLYCD (0.43) MLYCDRAB9AMT-CO2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6555541-B1 P2X7 receptor antagonists for treatment of inflammatory respiratory system disorders such as asthma; for example, 2-(3,4-Difluorophenylamino)-N-(2-methyl-5-piperazin-1-yl-methyl-phenyl) -acetamide, trihydrochloride ASTRAZENECA UK LIMITED (GB) 2003-04-29 US disclosed
EP-1185522-A1 SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AstraZeneca AB (SE) 2002-03-13 EP disclosed
WO-2000071529-A1 SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS ASTRAZENECA AB (SE) 2000-11-30 WO disclosed